You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
Justin Petrone covers consumer genomics, ancestry testing, and the microarray and biochip sector of the genomics market for GenomeWeb.
The company's approach relies on an initial point-of-care lateral flow assay followed by a confirmatory real-time PCR analysis run in its laboratories.
Iceni Diagnostics aims to deliver a rapid, point-of-care test that could differentiate the virus from more common flu strains using artificial glycan receptors.
Technology partners on the study include BioMérieux and SkylineDx, as well as Imperial College London's biomedical electronics unit.
Some believe that more could be done to help deliver diagnostics to the European market.
The researchers envisage deploying a point-of-care assay based on a fluorescent nanophotonics platform.
The company's approach involves using both fluorescence in situ hybridization and next-generation sequencing to provide clinicians with information.
IVD manufacturers are hoping questions related to the UK's pending exit from the EU, as well as the new European IVD Regulation, will soon be resolved.
The group aims to validate the tool, called OncoWatch, in a study involving nine countries this year.
While it continues to seek investments, the firm is also making preparations for an initial public offering on the Nasdaq First North exchange.
The British molecular diagnostics company received a CE-IVD mark for the assay, called BCA-1, in June, and launched the test in October.